JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Exponent (NASDAQ:EXPO) Stock

Exponent (NASDAQ:EXPO) had its price objective increased by research analysts at JPMorgan Chase & Co. from $80.00 to $90.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the business services provider’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 35.74% from the company’s current price.

Several other equities research analysts also recently issued reports on EXPO. Weiss Ratings reiterated a “hold (c-)” rating on shares of Exponent in a report on Friday, July 17th. UBS Group set a $72.00 price objective on shares of Exponent in a report on Friday. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.00.

Exponent Trading Up 2.7%

NASDAQ EXPO traded up $1.74 during trading hours on Friday, hitting $66.31. The company’s stock had a trading volume of 398,800 shares, compared to its average volume of 521,131. The company has a market capitalization of $3.22 billion, a PE ratio of 30.88 and a beta of 0.72. Exponent has a 52 week low of $51.91 and a 52 week high of $81.95. The company’s 50-day simple moving average is $59.82 and its two-hundred day simple moving average is $65.22.

Exponent (NASDAQ:EXPO) last issued its quarterly earnings data on Thursday, July 30th. The business services provider reported $0.60 EPS for the quarter, topping the consensus estimate of $0.55 by $0.05. Exponent had a return on equity of 27.94% and a net margin of 18.07%.The firm had revenue of $171.61 million during the quarter, compared to the consensus estimate of $144.99 million. During the same period in the prior year, the business posted $0.52 earnings per share. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. Research analysts anticipate that Exponent will post 2.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Catherine Corrigan sold 4,119 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $57.13, for a total transaction of $235,318.47. Following the completion of the sale, the chief executive officer directly owned 106,670 shares of the company’s stock, valued at $6,094,057.10. This trade represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Joseph Rakow sold 2,945 shares of Exponent stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $54.66, for a total value of $160,973.70. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 15,324 shares of company stock valued at $855,019. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Exponent

Several institutional investors have recently added to or reduced their stakes in the stock. United Services Automobile Association bought a new stake in Exponent in the first quarter worth about $270,000. Jane Street Group LLC grew its position in shares of Exponent by 1,481.0% during the 1st quarter. Jane Street Group LLC now owns 127,222 shares of the business services provider’s stock valued at $10,313,000 after acquiring an additional 119,175 shares during the period. Invesco Ltd. increased its stake in shares of Exponent by 3.3% during the 2nd quarter. Invesco Ltd. now owns 554,733 shares of the business services provider’s stock worth $41,444,000 after purchasing an additional 17,930 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Exponent in the 2nd quarter worth approximately $18,377,000. Finally, Walleye Capital LLC raised its holdings in shares of Exponent by 7.5% in the 2nd quarter. Walleye Capital LLC now owns 6,623 shares of the business services provider’s stock worth $495,000 after purchasing an additional 464 shares during the period. Institutional investors own 92.37% of the company’s stock.

Key Exponent News

Here are the key news stories impacting Exponent this week:

• Positive Sentiment: Exponent reported second-quarter earnings of $0.60 per diluted share, beating the $0.55 consensus estimate and rising from $0.52 a year earlier. Revenue reached approximately $171.6 million, exceeding expectations, while operating profit increased sharply. Exponent Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 net revenue growth outlook to 9%–10%, citing expanding AI-related demand. The upgraded guidance reinforces the view that Exponent’s technical consulting and engineering expertise is benefiting from new technology spending. Exponent raises 2026 net revenue growth view
• Positive Sentiment: The board authorized a $50 million increase to Exponent’s stock-repurchase program, potentially providing additional support for earnings per share and shareholder returns. It also declared a quarterly dividend of $0.31 per share, payable September 18 to shareholders of record September 4. Exponent dividend and repurchase announcement
• Neutral Sentiment: The company’s dividend offers a modest income component, with an indicated yield of roughly 1.9%. However, the latest quarter included slightly negative operating cash flow, which investors may monitor alongside the company’s growth investments.
• Negative Sentiment: Third-party data shows substantial insider selling over the past six months, including repeated sales by Chief Executive Officer Catherine Corrigan and no reported insider purchases. These transactions may reflect compensation or diversification, but could temper sentiment at a higher valuation. The data has not been independently verified.

About Exponent

Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.

Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.